Biosimilar Cost Savings: How Much Do They Really Save Compared to Original Biologics?

When you hear "generic drug," you probably think of a pill that costs a fraction of the brand-name version. But when it comes to biologics - complex drugs made from living cells - things are different. That’s where biosimilars come in. They’re not exact copies like generics, but they’re close enough to work the same way. And right now, they’re one of the biggest untapped opportunities to cut drug costs in the U.S. You might think biosimilars should slash prices by 80% or more, like generics do. But they don’t. Why? Because making a biologic isn’t like mixing chemicals in a lab. It’s like cloning a living organism to produce a drug. Even tiny changes in how it’s made can affect how it works. That’s why biosimilars cost more to develop than generics - and why their savings are more modest, but still huge. Let’s look at the numbers. In 2024 alone, biosimilars saved the U.S. healthcare system $20.2 billion. Since the first one hit the market in 2015, total savings have hit $56.2 billion. That’s not pocket change. That’s enough to cover treatment for millions of patients who otherwise couldn’t afford it. Take Humira, the most expensive drug in U.S. history. Before biosimilars, a single dose could cost over $7,000. By January 2025, with 10 FDA-approved biosimilars on the market - several of them labeled "interchangeable" - the list price dropped by as much as 85%. That’s not a small discount. That’s a revolution. But here’s the catch: list price isn’t what most people pay. The U.S. drug pricing system is built on rebates, discounts, and hidden deals between drugmakers, pharmacies, and insurers. So even if a biosimilar’s list price is 80% lower, the manufacturer of the original biologic might offer a rebate so big that the net price ends up almost the same. That’s why, as of 2023, originator biologics still made up 98.9% of all biologic spending - even with biosimilars available. The real savings happen when you look beyond the sticker price. Studies show that when biosimilars enter the market, the original drug’s price often drops too. In countries like Germany and Norway, biologic prices fell by 36% after biosimilars arrived. That’s competition at work. And it’s not just about cost. It’s about access. Since 2015, biosimilars have enabled over 460 million extra days of therapy - meaning patients who couldn’t afford the original drug got treated anyway. That’s not theoretical. That’s real people with rheumatoid arthritis, Crohn’s disease, or psoriasis getting their lives back. Now, let’s compare biosimilars to generics. Generics are simple. A small-molecule drug like aspirin or metformin has a fixed chemical structure. Once the patent expires, any manufacturer can make an identical copy. That’s why generics can be 80-90% cheaper. Biosimilars? Not so simple. They’re made from living cells - usually in bioreactors with yeast or hamster cells. The final product is a mixture of similar-but-not-identical molecules. Think of it like two handmade sweaters made from the same wool and pattern. They look alike, feel alike, and keep you warm the same way. But they’re not the same sweater. That’s why regulators require extensive testing to prove biosimilars are as safe and effective as the original. This complexity means biosimilars cost more to make. Development can take over a decade and cost $100 million to $200 million - compared to just $1-$5 million for a generic. So savings are more like 15-35% off the list price, not 80%. But when you multiply that across millions of doses, it adds up fast. Here’s where it gets even more interesting. The savings aren’t just from one biosimilar entering the market. They multiply. When a second biosimilar comes in within three years of the first, it nearly doubles the pressure on prices. For Stelara (ustekinumab), nine biosimilars launched in mid-2025 with prices up to 90% below the original. That’s not a coincidence. More competitors = lower prices. But here’s the problem: the U.S. has a massive biosimilar void. Of the 118 biologics expected to lose patent protection over the next 10 years, only 12 have biosimilars in development. That means 90% of future opportunities are sitting idle. Meanwhile, the EU has biosimilars in the pipeline for 73% of high-sales biologics. The U.S. is falling behind. Why? One reason is the patent system. Drugmakers stretch patents with legal tricks - filing for new formulations, delivery methods, or uses - to delay competition. Another reason is reimbursement. Pharmacy benefit managers (PBMs) often push for private-label biosimilars tied to their own contracts, which limits patient choice and keeps prices high. Employers and insurers can fix this. They can require patients to try a biosimilar before approving the original drug (called step therapy). They can build formularies that favor biosimilars. They can negotiate contracts that reward lower net costs instead of list prices. Some companies have already done it. One employer saved $1.53 million per year just by switching all employees from Humira to its biosimilar. Across all self-insured U.S. employers, switching just two biologics to biosimilars could save $1.4 billion annually. Patients win too. In commercial markets, out-of-pocket costs for biosimilars are 23% lower than for the original biologic. For someone paying $500 a month for a biologic, that’s $115 saved every month. That’s a car payment. That’s groceries. That’s not being forced to choose between medicine and rent. The big question is: why aren’t more people using biosimilars? One answer is fear. Some doctors and patients still think biosimilars are "inferior." But over 3.3 billion days of therapy have been given with no unique safety issues. The FDA, WHO, and European Medicines Agency all agree: biosimilars are as safe and effective as the originals. Another barrier is confusion. The system is designed to hide true costs. A biosimilar might have a list price of $1,000, but after rebates, the net price is $900. Meanwhile, the original biologic’s list price is $7,000 - but with a 70% rebate, its net price is $2,100. The PBM might still prefer the original because it gets a bigger cut from the rebate. That’s not a savings. That’s a trap. To cut through the noise, health systems need better data. Tools like Segal’s SHAPE database track utilization and spending patterns. They show exactly where the money is going. Without that, you’re flying blind. So what’s next? The FDA is making it easier to approve biosimilars. The Inflation Reduction Act is starting to change how Medicare Part D pays for drugs. And more employers are demanding transparency. But the biggest opportunity is still ahead. If the U.S. gets serious about biosimilar development - funding research, cutting patent abuse, and reforming rebate systems - we could save $234 billion over the next decade. That’s more than the entire Medicare Part D budget. The science is solid. The savings are real. The patients are ready. What’s missing is the will to change the system. Right now, we’re paying far more than we need to - for drugs that could be just as good, at a fraction of the cost. It’s not about replacing one drug with another. It’s about finally bringing competition to a market that’s been rigged for too long. The question isn’t whether biosimilars work. It’s whether we’re ready to let them.